Latest Naltrexone Stories
LA JOLLA, Calif., Dec.
- Patent for naltrexone SR formulation expected to extend Contrave protection to 2028 SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc.
SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc.
LA JOLLA, Calif., Oct.
DUBLIN, October 30, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/g7lhzm/global_and ) has announced the addition of the "Global
Affordable cessation drugs, combined with 12-step programs, help conquer addictions New York, NY (PRWEB) October 29, 2014 Opioid addiction is characterized
DeepResearchReports.com adds “2014 Deep Research Report on Global and China Naltrexone HCL Industry” and “2014 Deep Research Report on Global and China Nalbuphine HCL Industry” to its
- Orexigen expects to end 2014 with approximately $190 million in cash, cash equivalents and marketable securities SAN DIEGO, Oct. 15, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc.
ST. PAUL, Minn., Sept. 30, 2014 /PRNewswire/ -- In 2011, approximately 5.1 million people in the United States abused prescription pain relievers (e.g.
The FDA has approved the weight loss pill Contrave, a medication that will be used to treat obese adults in conjunction with a controlled diet and exercise.
- A gift; a largess; a gratuity; a present; a dole.